Prognosis
Industry Body Calls Russian Covid-19 Vaccine a Pandora’s Box
- Clinical trial group says Gamaleya vaccine needs more testing
- Russia is on the verge of registering vaccine for civilian use
This article is for subscribers only.
Russia’s race to allow civilian use of a potential coronavirus vaccine before clinical trials are complete could put people at risk, according to a local association of multinational pharmaceutical companies.
The government plans to give a vaccine developed by Moscow’s Gamaleya Institute conditional registration as early as this week, which would open the door to civilian use. Yet less than 100 people had officially received the inoculation against the epidemic by early August and its widespread use could be dangerous, the Association of Clinical Trials Organizations said in a letter sent to Health Minister Mikhail Murashko on Monday.